BioLineRx (BLRX) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.
- BioLineRx's Net Income towards Common Stockholders rose 4941.52% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 5208.92%. This contributed to the annual value of -$19.3 million for FY2024, which is 6207.47% up from last year.
- Per BioLineRx's latest filing, its Net Income towards Common Stockholders stood at -$1.9 million for Q3 2025, which was up 4941.52% from -$2.0 million recorded in Q2 2025.
- BioLineRx's Net Income towards Common Stockholders' 5-year high stood at -$1.9 million during Q3 2025, with a 5-year trough of -$17.5 million in Q4 2023.
- In the last 3 years, BioLineRx's Net Income towards Common Stockholders had a median value of -$3.9 million in 2024 and averaged -$6.6 million.
- In the last 5 years, BioLineRx's Net Income towards Common Stockholders skyrocketed by 6734.38% in 2024 and then soared by 4503.8% in 2025.
- BioLineRx's Net Income towards Common Stockholders (Quarter) stood at -$17.5 million in 2023, then soared by 54.75% to -$7.9 million in 2024, then soared by 76.03% to -$1.9 million in 2025.
- Its Net Income towards Common Stockholders stands at -$1.9 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$2.0 million for Q1 2025.